Tirapazamine-cisplatin: the synergy
1998

Tirapazamine and Cisplatin: A Promising Cancer Treatment

Sample size: 132 publication Evidence: moderate

Author Information

Author(s): U Gatzemeier, G Rodriguez, J Treat, V Miller, R von Roemeling, J Viallet, A Rey

Primary Institution: Department of Thoracic Oncology, Hospital Grosshansdorf

Hypothesis

Can tirapazamine combined with cisplatin improve treatment outcomes for patients with advanced non-small-cell lung cancer?

Conclusion

The combination of tirapazamine and cisplatin is safe and effective for treating advanced non-small-cell lung cancer.

Supporting Evidence

  • Tirapazamine showed a 25% objective response rate in patients with advanced NSCLC.
  • The median survival for patients treated with tirapazamine and cisplatin was 38.9 weeks.
  • Tirapazamine did not cause significant myelosuppression.
  • Acute, reversible hearing loss was the main dose-limiting toxicity observed.

Takeaway

Tirapazamine is a new drug that works well with cisplatin to help treat lung cancer, and it doesn't cause many of the bad side effects that other treatments do.

Methodology

The study involved phase I and phase II clinical trials with a total of 132 patients receiving various doses of tirapazamine and cisplatin.

Limitations

The study primarily focused on patients with advanced non-small-cell lung cancer, which may limit the generalizability of the results.

Participant Demographics

{"total_patients":132,"gender_distribution":{"male":77,"female":55},"stage_distribution":{"regional":42,"distant":90}}

Statistical Information

Confidence Interval

17.8-33.3

Statistical Significance

p<0.05

Want to read the original?

Access the complete publication on the publisher's website

View Original Publication